Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016, Article ID 5170402, 11 pages
http://dx.doi.org/10.1155/2016/5170402
Review Article

Pathogenesis of Nonalcoholic Steatohepatitis: Interactions between Liver Parenchymal and Nonparenchymal Cells

Department of Pharmacology, Toxicology & Therapeutics, University of Kansas Medical Center, Kansas City, KS 66160, USA

Received 30 June 2016; Accepted 22 September 2016

Academic Editor: Michel Fausther

Copyright © 2016 Nancy Magee et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. A. Kirpich, L. N. Gobejishvili, M. Bon Homme et al., “Integrated hepatic transcriptome and proteome analysis of mice with high-fat diet-induced nonalcoholic fatty liver disease,” The Journal of Nutritional Biochemistry, vol. 22, no. 1, pp. 38–45, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. V. Uppal, S. Mansoor, and K. N. Furuya, “Pediatric non-alcoholic fatty liver disease,” Current Gastroenterology Reports, vol. 18, no. 5, article 24, 2016. View at Publisher · View at Google Scholar
  3. Z. M. Younossi, A. B. Koenig, D. Abdelatif, Y. Fazel, L. Henry, and M. Wymer, “Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes,” Hepatology, vol. 64, no. 1, pp. 73–84, 2016. View at Publisher · View at Google Scholar
  4. K. Bettermann, T. Hohensee, and J. Haybaeck, “Steatosis and steatohepatitis: complex disorders,” International Journal of Molecular Sciences, vol. 15, no. 6, pp. 9924–9944, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Baffy, “Kupffer cells in non-alcoholic fatty liver disease: the emerging view,” Journal of Hepatology, vol. 51, no. 1, pp. 212–223, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. N. S. Betrapally, P. M. Gillevet, and J. S. Bajaj, “Changes in the intestinal microbiome and alcoholic and nonalcoholic liver diseases: causes or effects?” Gastroenterology, vol. 150, no. 8, pp. 1745–1755.e3, 2016. View at Publisher · View at Google Scholar
  7. A. Feldman, S. K. Eder, T. K. Felder et al., “Clinical and metabolic characterization of lean caucasian subjects with non-alcoholic fatty liver,” The American Journal of Gastroenterology, 2016. View at Publisher · View at Google Scholar
  8. B. Vos, C. Moreno, N. Nagy et al., “Lean non-alcoholic fatty liver disease (Lean-NAFLD): a major cause of cryptogenic liver disease,” Acta Gastro-Enterologica Belgica, vol. 74, no. 3, pp. 389–394, 2011. View at Google Scholar · View at Scopus
  9. R.-N. Feng, S.-S. Du, C. Wang et al., “Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population,” World Journal of Gastroenterology, vol. 20, no. 47, pp. 17932–17940, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Ludwig, T. R. Viggiano, D. B. McGill, and B. J. Oh, “Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease,” Mayo Clinic Proceedings, vol. 55, no. 7, pp. 434–438, 1980. View at Google Scholar · View at Scopus
  11. N. Chalasani, Z. Younossi, J. E. Lavine et al., “The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association,” Hepatology, vol. 55, no. 6, pp. 2005–2023, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Wobser, C. Dorn, T. S. Weiss et al., “Lipid accumulation in hepatocytes induces fibrogenic activation of hepatic stellate cells,” Cell Research, vol. 19, no. 8, pp. 996–1005, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Brenner, L. Galluzzi, O. Kepp, and G. Kroemer, “Decoding cell death signals in liver inflammation,” Journal of Hepatology, vol. 59, no. 3, pp. 583–594, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. D. M. Lebensztejn, M. Flisiak-Jackiewicz, I. Białokoz-Kalinowska, A. Bobrus-Chociej, and I. Kowalska, “Hepatokines and non-alcoholic fatty liver disease,” Acta Biochimica Polonica, vol. 63, no. 3, pp. 459–467, 2016. View at Publisher · View at Google Scholar
  15. M. Ganz and G. Szabo, “Immune and inflammatory pathways in NASH,” Hepatology International, vol. 7, no. S2, pp. 771–781, 2013. View at Publisher · View at Google Scholar
  16. S. McPherson, T. Hardy, E. Henderson, A. D. Burt, C. P. Day, and Q. M. Anstee, “Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management,” Journal of Hepatology, vol. 62, no. 5, pp. 1148–1155, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. C. P. Day and O. F. W. James, “Hepatic steatosis: innocent bystander or guilty party?” Hepatology, vol. 27, no. 6, pp. 1463–1466, 1998. View at Publisher · View at Google Scholar · View at Scopus
  18. Y.-T. Zhan and W. An, “Roles of liver innate immune cells in nonalcoholic fatty liver disease,” World Journal of Gastroenterology, vol. 16, no. 37, pp. 4652–4660, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. C. P. Day and O. F. W. James, “Steatohepatitis: a tale of two ‘Hits’?” Gastroenterology, vol. 114, no. 4 I, pp. 842–845, 1998. View at Publisher · View at Google Scholar · View at Scopus
  20. W. Peverill, L. W. Powell, and R. Skoien, “Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation,” International Journal of Molecular Sciences, vol. 15, no. 5, pp. 8591–8638, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. S. L. Friedman, “Liver fibrosis in 2012: convergent pathways that cause hepatic fibrosis in NASH,” Nature Reviews Gastroenterology & Hepatology, vol. 10, no. 2, pp. 71–72, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Tilg and A. R. Moschen, “Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis,” Hepatology, vol. 52, no. 5, pp. 1836–1846, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Romeo, J. Kozlitina, C. Xing et al., “Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease,” Nature Genetics, vol. 40, no. 12, pp. 1461–1465, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. N. Chalasani, X. Guo, R. Loomba et al., “Genome-wide association study identifies variants associated with histologic features of nonalcoholic fatty liver disease,” Gastroenterology, vol. 139, no. 5, pp. 1567.e6–1576.e6, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. E. K. Speliotes, L. M. Yerges-Armstrong, J. Wu et al., “Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits,” PLoS Genetics, vol. 7, no. 3, article e1001324, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. Y. Rotman, C. Koh, J. M. Zmuda, D. E. Kleiner, and T. J. Liang, “The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease,” Hepatology, vol. 52, no. 3, pp. 894–903, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. R. Xu, A. Tao, S. Zhang, Y. Deng, and G. Chen, “Association between patatin-like phospholipase domain containing 3 gene (PNPLA3) polymorphisms and nonalcoholic fatty liver disease: a HuGE review and meta-analysis,” Scientific Reports, vol. 5, article 9284, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. N. Santoro, R. Kursawe, E. D'Adamo et al., “A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents,” Hepatology, vol. 52, no. 4, pp. 1281–1290, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. L. Valenti, A. Al-Serri, A. K. Daly et al., “Homozygosity for the patatin-like phospholipase-3/adiponutrin i148m polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease,” Hepatology, vol. 51, no. 4, pp. 1209–1217, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. S. He, C. McPhaul, J. Z. Li et al., “A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis,” The Journal of Biological Chemistry, vol. 285, no. 9, pp. 6706–6715, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. R. R. Kanherkar, N. Bhatia-Dey, and A. B. Csoka, “Epigenetics across the human lifespan,” Frontiers in Cell and Developmental Biology, vol. 2, article 49, 2014. View at Publisher · View at Google Scholar
  32. C. Xu, G. Wang, Y. Hao, J. Zhi, L. Zhang, and C. Chang, “Correlation analysis between gene expression profile of rat liver tissues and high-fat emulsion-induced nonalcoholic fatty liver,” Digestive Diseases and Sciences, vol. 56, no. 8, pp. 2299–2308, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. C. J. Pirola, T. F. Gianotti, A. L. Burgueño et al., “Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease,” Gut, vol. 62, no. 9, pp. 1356–1363, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. W. Tian, H. Xu, F. Fang, Q. Chen, Y. Xu, and A. Shen, “Brahma-related gene 1 bridges epigenetic regulation of proinflammatory cytokine production to steatohepatitis in mice,” Hepatology, vol. 58, no. 2, pp. 576–588, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. M. D. Hirschey, T. Shimazu, E. Jing et al., “SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome,” Molecular Cell, vol. 44, no. 2, pp. 177–190, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. O. Cheung, P. Puri, C. Eicken et al., “Nonalcoholic steatohepatitis is associated with altered hepatic microRNA expression,” Hepatology, vol. 48, no. 6, pp. 1810–1820, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. N. Nakanishi, Y. Nakagawa, N. Tokushige et al., “The up-regulation of microRNA-335 is associated with lipid metabolism in liver and white adipose tissue of genetically obese mice,” Biochemical and Biophysical Research Communications, vol. 385, no. 4, pp. 492–496, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. I. P. Pogribny, A. Starlard-Davenport, V. P. Tryndyak et al., “Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice,” Laboratory Investigation, vol. 90, no. 10, pp. 1437–1446, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. E. M. Brunt, D. E. Kleiner, L. A. Wilson, P. Belt, B. A. Neuschwander-Tetri, and NASH Clinical Research Network (CRN), “Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings,” Hepatology, vol. 53, no. 3, pp. 810–820, 2011. View at Publisher · View at Google Scholar
  40. Z. Z. Li, M. Berk, T. M. McIntyre, and A. E. Feldstein, “Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase,” The Journal of Biological Chemistry, vol. 284, no. 9, pp. 5637–5644, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Liu, L. Han, L. Zhu, and Y. Yu, “Free fatty acids, not triglycerides, are associated with non-alcoholic liver injury progression in high fat diet induced obese rats,” Lipids in Health and Disease, vol. 15, no. 1, article 27, 2016. View at Publisher · View at Google Scholar · View at Scopus
  42. M. C. Arkan, A. L. Hevener, F. R. Greten et al., “IKK-β links inflammation to obesity-induced insulin resistance,” Nature Medicine, vol. 11, no. 2, pp. 191–198, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. X.-H. Li, K. C.-Y. McGrath, S. Nammi, A. K. Heather, and B. D. Roufogalis, “Attenuation of liver pro-inflammatory responses by zingiber officinale via inhibition of NF-kappa B activation in high-fat diet-fed rats,” Basic and Clinical Pharmacology and Toxicology, vol. 110, no. 3, pp. 238–244, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. M. L. Chaisson, J. T. Brooling, W. Ladiges, S. Tsai, and N. Fausto, “Hepatocyte-specific inhibition of NF-κB leads to apoptosis after TNF treatment, but not after partial hepatectomy,” The Journal of Clinical Investigation, vol. 110, no. 2, pp. 193–202, 2002. View at Publisher · View at Google Scholar · View at Scopus
  45. X.-Q. Zhang, C.-F. Xu, C.-H. Yu, W.-X. Chen, and Y.-M. Li, “Role of endoplasmic reticulum stress in the pathogenesis of nonalcoholic fatty liver disease,” World Journal of Gastroenterology, vol. 20, no. 7, pp. 1768–1776, 2014. View at Publisher · View at Google Scholar · View at Scopus
  46. A. D. Lake, P. Novak, R. N. Hardwick et al., “The adaptive endoplasmic reticulum stress response to lipotoxicity in progressive human nonalcoholic fatty liver disease,” Toxicological Sciences, vol. 137, no. 1, Article ID kft230, pp. 26–35, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. P. J. Meakin, S. Chowdhry, R. S. Sharma et al., “Susceptibility of Nrf2-null mice to steatohepatitis and cirrhosis upon consumption of a high-fat diet is associated with oxidative stress, perturbation of the unfolded protein response, and disturbance in the expression of metabolic enzymes but not with insulin resistance,” Molecular and Cellular Biology, vol. 34, no. 17, pp. 3305–3320, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Kandel-Kfir, T. Almog, A. Shaish et al., “Interleukin-1α deficiency attenuates endoplasmic reticulum stress-induced liver damage and CHOP expression in mice,” Journal of Hepatology, vol. 63, no. 4, pp. 926–933, 2015. View at Publisher · View at Google Scholar · View at Scopus
  49. L. Vonghia, P. Michielsen, and S. Francque, “Immunological mechanisms in the pathophysiology of non-alcoholic steatohepatitis,” International Journal of Molecular Sciences, vol. 14, no. 10, pp. 19867–19890, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. X. Wan, C. Xu, C. Yu, and Y. Li, “Role of NLRP3 inflammasome in the progression of NAFLD to NASH,” Canadian Journal of Gastroenterology and Hepatology, vol. 2016, Article ID 6489012, 7 pages, 2016. View at Publisher · View at Google Scholar
  51. V. L. Gadd, R. Skoien, E. E. Powell et al., “The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease,” Hepatology, vol. 59, no. 4, pp. 1393–1405, 2014. View at Publisher · View at Google Scholar · View at Scopus
  52. V. Bieghs and C. Trautwein, “The innate immune response during liver inflammation and metabolic disease,” Trends in Immunology, vol. 34, no. 9, pp. 446–452, 2013. View at Publisher · View at Google Scholar · View at Scopus
  53. W. S. Haubrich, “Kupffer of Kupffer cells,” Gastroenterology, vol. 127, no. 1, p. 16, 2004. View at Publisher · View at Google Scholar · View at Scopus
  54. L. Li and B.-E. Wang, “Kupffer cells and liver fibrosis,” Zhonghua Gan Zang Bing Za Zhi, vol. 15, no. 7, pp. 559–560, 2007. View at Google Scholar · View at Scopus
  55. F. Tacke and H. W. Zimmermann, “Macrophage heterogeneity in liver injury and fibrosis,” Journal of Hepatology, vol. 60, no. 5, pp. 1090–1096, 2014. View at Publisher · View at Google Scholar · View at Scopus
  56. M. Mouzaki, E. M. Comelli, B. M. Arendt et al., “Intestinal microbiota in patients with nonalcoholic fatty liver disease,” Hepatology, vol. 58, no. 1, pp. 120–127, 2013. View at Publisher · View at Google Scholar · View at Scopus
  57. J. Henao-Mejia, E. Elinav, C. Jin et al., “Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity,” Nature, vol. 482, no. 7384, pp. 179–185, 2012. View at Publisher · View at Google Scholar · View at Scopus
  58. C. S. Schaffert, M. J. Duryee, C. D. Hunter et al., “Alcohol metabolites and lipopolysaccharide: roles in the development and/or progression of alcoholic liver disease,” World Journal of Gastroenterology, vol. 15, no. 10, pp. 1209–1218, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. L. Zhu, S. S. Baker, C. Gill et al., “Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH,” Hepatology, vol. 57, no. 2, pp. 601–609, 2013. View at Publisher · View at Google Scholar · View at Scopus
  60. V. Bieghs, P. C. N. Rensen, M. H. Hofker, and R. Shiri-Sverdlov, “NASH and atherosclerosis are two aspects of a shared disease: central role for macrophages,” Atherosclerosis, vol. 220, no. 2, pp. 287–293, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. P. Italiani and D. Boraschi, “From monocytes to M1/M2 macrophages: phenotypical vs. functional differentiation,” Frontiers in Immunology, vol. 5, article 514, 2014. View at Publisher · View at Google Scholar · View at Scopus
  62. J. Wan, M. Benkdane, F. Teixeira-Clerc et al., “M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease,” Hepatology, vol. 59, no. 1, pp. 130–142, 2014. View at Publisher · View at Google Scholar · View at Scopus
  63. A. Sica and A. Mantovani, “Macrophage plasticity and polarization: in vivo veritas,” The Journal of Clinical Investigation, vol. 122, no. 3, pp. 787–795, 2012. View at Publisher · View at Google Scholar · View at Scopus
  64. F. Xiu, M. Catapano, L. Diao, M. Stanojcic, and M. G. Jeschke, “Prolonged endoplasmic reticulum-stressed hepatocytes drive an alternative macrophage polarization,” Shock, vol. 44, no. 1, pp. 44–51, 2015. View at Publisher · View at Google Scholar · View at Scopus
  65. Z. Wenfeng, W. Yakun, M. Di, G. Jianping, W. Chuanxin, and H. Chun, “Kupffer cells: increasingly significant role in nonalcoholic fatty liver disease,” Annals of Hepatology, vol. 13, no. 5, pp. 489–495, 2014. View at Google Scholar · View at Scopus
  66. A. Eguchi, A. Wree, and A. E. Feldstein, “Biomarkers of liver cell death,” Journal of Hepatology, vol. 60, no. 5, pp. 1063–1074, 2014. View at Publisher · View at Google Scholar · View at Scopus
  67. G. Kolios, V. Valatas, and E. Kouroumalis, “Role of Kupffer cells in the pathogenesis of liver disease,” World Journal of Gastroenterology, vol. 12, no. 46, pp. 7413–7420, 2006. View at Publisher · View at Google Scholar · View at Scopus
  68. W. Huang, A. Metlakunta, N. Dedousis et al., “Depletion of liver Kupffer cells prevents the development of diet-induced hepatic steatosis and insulin resistance,” Diabetes, vol. 59, no. 2, pp. 347–357, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. T. Sharifnia, J. Antoun, T. G. C. Verriere et al., “Hepatic TLR4 signaling in obese NAFLD,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 309, no. 4, pp. G270–G278, 2015. View at Publisher · View at Google Scholar · View at Scopus
  70. S. M. A. Walenbergh, G. H. Koek, V. Bieghs, and R. Shiri-Sverdlov, “Non-alcoholic steatohepatitis: the role of oxidized low-density lipoproteins,” Journal of Hepatology, vol. 58, no. 4, pp. 801–810, 2013. View at Publisher · View at Google Scholar · View at Scopus
  71. V. Bieghs, F. Verheyen, P. J. van Gorp et al., “Internalization of modified lipids by CD36 and SR-A leads to hepatic inflammation and lysosomal cholesterol storage in Kupffer cells,” PLoS ONE, vol. 7, no. 3, Article ID e34378, 2012. View at Publisher · View at Google Scholar · View at Scopus
  72. V. Bieghs, P. J. van Gorp, S. M. A. Walenbergh et al., “Specific immunization strategies against oxidized low-density lipoprotein: a novel way to reduce nonalcoholic steatohepatitis in mice,” Hepatology, vol. 56, no. 3, pp. 894–903, 2012. View at Publisher · View at Google Scholar · View at Scopus
  73. R. Xu, H. Huang, Z. Zhang, and F.-S. Wang, “The role of neutrophils in the development of liver diseases,” Cellular & Molecular Immunology, vol. 11, no. 3, pp. 224–231, 2014. View at Publisher · View at Google Scholar · View at Scopus
  74. S. S. Rensen, Y. Slaats, J. Nijhuis et al., “Increased hepatic myeloperoxidase activity in obese subjects with nonalcoholic steatohepatitis,” The American Journal of Pathology, vol. 175, no. 4, pp. 1473–1482, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. N. Alkhouri, G. Morris-Stiff, C. Campbell et al., “Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease,” Liver International, vol. 32, no. 2, pp. 297–302, 2012. View at Publisher · View at Google Scholar · View at Scopus
  76. R. Ibusuki, H. Uto, S. Arima et al., “Transgenic expression of human neutrophil peptide-1 enhances hepatic fibrosis in mice fed a choline-deficient, L-amino acid-defined diet,” Liver International, vol. 33, no. 10, pp. 1549–1556, 2013. View at Publisher · View at Google Scholar · View at Scopus
  77. S. Talukdar, D. Y. Oh, G. Bandyopadhyay et al., “Neutrophils mediate insulin resistance in mice fed a high-fat diet through secreted elastase,” Nature Medicine, vol. 18, no. 9, pp. 1407–1412, 2012. View at Publisher · View at Google Scholar · View at Scopus
  78. R. Meli, G. M. Raso, and A. Calignano, “Role of innate immune response in non-alcoholic fatty liver disease: metabolic complications and therapeutic tools,” Frontiers in Immunology, vol. 5, article 177, 2014. View at Publisher · View at Google Scholar · View at Scopus
  79. S. Romagnani, “Type 1 T helper and type 2 T helper cells: functions, regulation and role in protection and disease,” International Journal of Clinical & Laboratory Research, vol. 21, no. 2, pp. 152–158, 1992. View at Publisher · View at Google Scholar · View at Scopus
  80. H. Sell, C. Habich, and J. Eckel, “Adaptive immunity in obesity and insulin resistance,” Nature Reviews Endocrinology, vol. 8, no. 12, pp. 709–716, 2012. View at Publisher · View at Google Scholar · View at Scopus
  81. E. M. Brunt, “Pathology of nonalcoholic fatty liver disease,” Nature Reviews Gastroenterology & Hepatology, vol. 7, no. 4, pp. 195–203, 2010. View at Publisher · View at Google Scholar · View at Scopus
  82. J. R. Henning, C. S. Graffeo, A. Rehman et al., “Dendritic cells limit fibroinflammatory injury in nonalcoholic steatohepatitis in mice,” Hepatology, vol. 58, no. 2, pp. 589–602, 2013. View at Publisher · View at Google Scholar · View at Scopus
  83. Y. Tang, Z. Bian, L. Zhao et al., “Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease,” Clinical and Experimental Immunology, vol. 166, no. 2, pp. 281–290, 2011. View at Publisher · View at Google Scholar · View at Scopus
  84. I. T. W. Harley, T. E. Stankiewicz, D. A. Giles et al., “IL-17 signaling accelerates the progression of nonalcoholic fatty liver disease in mice,” Hepatology, vol. 59, no. 5, pp. 1830–1839, 2014. View at Publisher · View at Google Scholar · View at Scopus
  85. M. Rau, A.-K. Schilling, J. Meertens et al., “Progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis is marked by a higher frequency of Th17 cells in the liver and an increased Th17/resting regulatory T cell ratio in peripheral blood and in the liver,” The Journal of Immunology, vol. 196, no. 1, pp. 97–105, 2016. View at Publisher · View at Google Scholar · View at Scopus
  86. D. A. Winer, S. Winer, M. H. Y. Chng, L. Shen, and E. G. Engleman, “B Lymphocytes in obesity-related adipose tissue inflammation and insulin resistance,” Cellular and Molecular Life Sciences, vol. 71, no. 6, pp. 1033–1043, 2014. View at Publisher · View at Google Scholar · View at Scopus
  87. S. Sutti, A. Jindal, I. Locatelli et al., “Adaptive immune responses triggered by oxidative stress contribute to hepatic inflammation in NASH,” Hepatology, vol. 59, no. 3, pp. 886–897, 2014. View at Publisher · View at Google Scholar · View at Scopus
  88. E. Albano, E. Mottaran, M. Vidali et al., “Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis,” Gut, vol. 54, no. 7, pp. 987–993, 2005. View at Publisher · View at Google Scholar · View at Scopus
  89. V. Nobili, M. Parola, A. Alisi et al., “Oxidative stress parameters in paediatric non-alcoholic fatty liver disease,” International Journal of Molecular Medicine, vol. 26, no. 4, pp. 471–476, 2010. View at Publisher · View at Google Scholar · View at Scopus
  90. D. A. Winer, S. Winer, L. Shen et al., “B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies,” Nature Medicine, vol. 17, no. 5, pp. 610–617, 2011. View at Publisher · View at Google Scholar · View at Scopus
  91. L. G. Ng, A. P. R. Sutherland, R. Newton et al., “B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells,” Journal of Immunology, vol. 173, no. 2, pp. 807–817, 2004. View at Publisher · View at Google Scholar · View at Scopus
  92. K. Kawasaki, M. Abe, F. Tada et al., “Blockade of B-cell-activating factor signaling enhances hepatic steatosis induced by a high-fat diet and improves insulin sensitivity,” Laboratory Investigation, vol. 93, no. 3, pp. 311–321, 2013. View at Publisher · View at Google Scholar · View at Scopus
  93. D.-H. Kim and M.-S. Do, “BAFF knockout improves systemic inflammation via regulating adipose tissue distribution in high-fat diet-induced obesity,” Experimental & Molecular Medicine, vol. 47, article e129, 2015. View at Publisher · View at Google Scholar · View at Scopus
  94. J. Bhattacharjee, J. M. Kumar, S. Arindkar et al., “Role of immunodeficient animal models in the development of fructose induced NAFLD,” Journal of Nutritional Biochemistry, vol. 25, no. 2, pp. 219–226, 2014. View at Publisher · View at Google Scholar · View at Scopus
  95. G. Szabo and T. Csak, “Inflammasomes in liver diseases,” Journal of Hepatology, vol. 57, no. 3, pp. 642–654, 2012. View at Publisher · View at Google Scholar · View at Scopus
  96. T. Csak, M. Ganz, J. Pespisa, K. Kodys, A. Dolganiuc, and G. Szabo, “Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells,” Hepatology, vol. 54, no. 1, pp. 133–144, 2011. View at Publisher · View at Google Scholar · View at Scopus
  97. A. Wree, M. D. McGeough, C. A. Peña et al., “NLRP3 inflammasome activation is required for fibrosis development in NAFLD,” Journal of Molecular Medicine, vol. 92, no. 10, pp. 1069–1082, 2014. View at Publisher · View at Google Scholar · View at Scopus
  98. Y. Kamari, A. Shaish, E. Vax et al., “Lack of interleukin-1α or interleukin-1β inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice,” Journal of Hepatology, vol. 55, no. 5, pp. 1086–1094, 2011. View at Publisher · View at Google Scholar · View at Scopus
  99. L. J. Dixon, M. Berk, S. Thapaliya, B. G. Papouchado, and A. E. Feldstein, “Caspase-1-mediated regulation of fibrogenesis in diet-induced steatohepatitis,” Laboratory Investigation, vol. 92, no. 5, pp. 713–723, 2012. View at Publisher · View at Google Scholar · View at Scopus
  100. R. Bataller and D. A. Brenner, “Liver fibrosis,” The Journal of Clinical Investigation, vol. 115, no. 2, pp. 209–218, 2005. View at Publisher · View at Google Scholar · View at Scopus
  101. N. Kawada, “Cytoglobin as a marker of hepatic stellate cell-derived myofibroblasts,” Frontiers in Physiology, vol. 6, article 329, 2015. View at Publisher · View at Google Scholar · View at Scopus
  102. R. Safadi and S. L. Friedman, “Hepatic fibrosis—role of hepatic stellate cell activation,” Medscape General Medicine, vol. 4, no. 3, article 27, 2002. View at Google Scholar
  103. G. Ramadori and B. Saile, “Portal tract fibrogenesis in the liver,” Laboratory Investigation, vol. 84, no. 2, pp. 153–159, 2004. View at Publisher · View at Google Scholar · View at Scopus
  104. A. M. Gressner and R. Weiskirchen, “Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-β as major players and therapeutic targets,” Journal of Cellular and Molecular Medicine, vol. 10, no. 1, pp. 76–99, 2006. View at Publisher · View at Google Scholar · View at Scopus
  105. R. K. Moreira, “Hepatic stellate cells and liver fibrosis,” Archives of Pathology and Laboratory Medicine, vol. 131, no. 11, pp. 1728–1734, 2007. View at Google Scholar · View at Scopus
  106. R. Weiskirchen and F. Tacke, “Cellular and molecular functions of hepatic stellate cells in inflammatory responses and liver immunology,” Hepatobiliary Surgery and Nutrition, vol. 3, no. 6, pp. 344–363, 2014. View at Google Scholar
  107. M. Thapa, R. Chinnadurai, V. M. Velazquez et al., “Liver fibrosis occurs through dysregulation of MyD88-dependent innate B-cell activity,” Hepatology, vol. 61, no. 6, pp. 2067–2079, 2015. View at Publisher · View at Google Scholar · View at Scopus
  108. P. Kocabayoglu and S. L. Friedman, “Cellular basis of hepatic fibrosis and its role in inflammation and cancer,” Frontiers in Bioscience - Scholar, vol. 5, no. 1, pp. 217–230, 2013. View at Google Scholar · View at Scopus
  109. K. Uchio, B. Tuchweber, N. Manabe, G. Gabbiani, J. Rosenbaum, and A. Desmoulière, “Cellular retinol-binding protein-1 expression and modulation during in vivo and in vitro myofibroblastic differentiation of rat hepatic stellate cells and portal fibroblasts,” Laboratory Investigation, vol. 82, no. 5, pp. 619–628, 2002. View at Publisher · View at Google Scholar · View at Scopus
  110. H. Motoyama, T. Komiya, L. T. T. Thuy et al., “Cytoglobin is expressed in hepatic stellate cells, but not in myofibroblasts, in normal and fibrotic human liver,” Laboratory Investigation, vol. 94, no. 2, pp. 192–207, 2014. View at Publisher · View at Google Scholar · View at Scopus
  111. D. Kobold, A. Grundmann, F. Piscaglia et al., “Expression of reelin in hepatic stellate cells and during hepatic tissue repair: a novel marker for the differentiation of HSC from other liver myofibroblasts,” Journal of Hepatology, vol. 36, no. 5, pp. 607–613, 2002. View at Publisher · View at Google Scholar · View at Scopus
  112. J. A. Dranoff, E. A. Kruglov, S. C. Robson, N. Braun, H. Zimmermann, and J. Sévigny, “The ecto-nucleoside triphosphate diphosphohydrolase NTPDase2/CD39l1 is expressed in a novel functional compartment within the liver,” Hepatology, vol. 36, no. 5, pp. 1135–1144, 2002. View at Publisher · View at Google Scholar · View at Scopus
  113. G. Ö. Elpek, “Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: an update,” World Journal of Gastroenterology, vol. 20, no. 23, pp. 7260–7276, 2014. View at Publisher · View at Google Scholar · View at Scopus
  114. U. E. Lee and S. L. Friedman, “Mechanisms of hepatic fibrogenesis,” Best Practice & Research: Clinical Gastroenterology, vol. 25, no. 2, pp. 195–206, 2011. View at Publisher · View at Google Scholar · View at Scopus
  115. J. Wanninger, M. Neumeier, C. Hellerbrand et al., “Lipid accumulation impairs adiponectin-mediated induction of activin A by increasing TGFbeta in primary human hepatocytes,” Biochimica et Biophysica Acta (BBA)—Molecular and Cell Biology of Lipids, vol. 1811, no. 10, pp. 626–633, 2011. View at Publisher · View at Google Scholar · View at Scopus
  116. R. Bansal, J. van Baarlen, G. Storm, and J. Prakash, “The interplay of the Notch signaling in hepatic stellate cells and macrophages determines the fate of liver fibrogenesis,” Scientific Reports, vol. 5, Article ID 18272, 2015. View at Publisher · View at Google Scholar · View at Scopus
  117. B. Schnabl, C. A. Bradham, B. L. Bennett, A. M. Manning, B. Stefanovic, and D. A. Brenner, “TAK1/JNK and p38 have opposite effects on rat hepatic stellate cells,” Hepatology, vol. 34, no. 5, pp. 953–963, 2001. View at Publisher · View at Google Scholar · View at Scopus
  118. L. A. Borthwick and D. A. Mann, “Liver: osteopontin and HMGB1: novel regulators of HSC activation,” Nature Reviews Gastroenterology & Hepatology, vol. 13, no. 6, pp. 320–322, 2016. View at Google Scholar
  119. C. D. Guy, A. Suzuki, M. Zdanowicz et al., “Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease,” Hepatology, vol. 55, no. 6, pp. 1711–1721, 2012. View at Publisher · View at Google Scholar · View at Scopus
  120. A. Dajani and A. AbuHammour, “Treatment of nonalcoholic fatty liver disease: where do we stand? An overview,” Saudi Journal of Gastroenterology, vol. 22, no. 2, pp. 91–105, 2016. View at Google Scholar
  121. M. C. Cave, H. B. Clair, J. E. Hardesty et al., “Nuclear receptors and nonalcoholic fatty liver disease,” Biochimica et Biophysica Acta, vol. 1859, no. 9, pp. 1083–1099, 2016. View at Publisher · View at Google Scholar
  122. J. A. López-Velázquez, L. D. Carrillo-Córdova, N. C. Chávez-Tapia, M. Uribe, and N. Méndez-Sánchez, “Nuclear receptors in nonalcoholic fatty liver disease,” Journal of Lipids, vol. 2012, Article ID 139875, 10 pages, 2012. View at Publisher · View at Google Scholar
  123. A. C. Li and C. K. Glass, “The macrophage foam cell as a target for therapeutic intervention,” Nature Medicine, vol. 8, no. 11, pp. 1235–1242, 2002. View at Publisher · View at Google Scholar · View at Scopus
  124. J. K. Dowman, J. W. Tomlinson, and P. N. Newsome, “Pathogenesis of non-alcoholic fatty liver disease,” Quarterly Journal of Medicine, vol. 103, no. 2, pp. 71–83, 2009. View at Publisher · View at Google Scholar · View at Scopus
  125. A. J. Sanyal, N. Chalasani, K. V. Kowdley et al., “Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis,” The New England Journal of Medicine, vol. 362, no. 18, pp. 1675–1685, 2010. View at Publisher · View at Google Scholar · View at Scopus
  126. C. D. Guy, A. Suzuki, M. F. Abdelmalek, J. L. Burchette, and A. M. Diehl, “Treatment response in the PIVENS trial is associated with decreased hedgehog pathway activity,” Hepatology, vol. 61, no. 1, pp. 98–107, 2015. View at Publisher · View at Google Scholar · View at Scopus
  127. P. Hirsova and G. J. Gores, “Ballooned hepatocytes, undead cells, sonic hedgehog, and vitamin E: therapeutic implications for nonalcoholic steatohepatitis,” Hepatology, vol. 61, no. 1, pp. 15–17, 2015. View at Publisher · View at Google Scholar · View at Scopus
  128. Y. Liu, R. Wei, and T.-P. Hong, “Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease,” World Journal of Gastroenterology, vol. 20, no. 27, pp. 9090–9097, 2014. View at Publisher · View at Google Scholar · View at Scopus
  129. J. K. Dyson, Q. M. Anstee, and S. McPherson, “Non-alcoholic fatty liver disease: a practical approach to treatment,” Frontline Gastroenterology, vol. 5, no. 4, pp. 277–286, 2014. View at Publisher · View at Google Scholar
  130. L. Eslami, S. Merat, and S. Nasseri-Moghaddam, “Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD): a systematic review,” Middle East Journal of Digestive Diseases, vol. 1, no. 2, pp. 89–99, 2009. View at Google Scholar